Session » Osteoarthritis – Clinical Poster II

Date: Tuesday, November 12, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2193

“If It Was Unicorn Dust I’d Have It Again.” Patient Experiences of Hip Osteoarthritis and Treatments in the Hip Injection Trial

9:00AM-11:00AM: Abstract Number: 2184

A Flexion Contracture Is a Risk Factor for Radiographic Progression and Earlier Need for Arthroplasty in Knee Osteoarthritis: Data from the Osteoarthritis Initiative

9:00AM-11:00AM: Abstract Number: 2187

A Low Cartilage Formation & Repair Endotype Predicts Radiographic Progression in Symptomatic Knee Osteoarthritis Patients and Identifies Optimal Responders to a Potential OA Treatment

9:00AM-11:00AM: Abstract Number: 2176

A Novel Composite Score Reflecting Disease Activity Predicts Future Knee Replacements: Data from the Osteoarthritis Initiative

9:00AM-11:00AM: Abstract Number: 2178

Associations Between Baseline and Longitudinal Quantitative Joint Space Width and Incident Hip Osteoarthritis: The Johnston County Osteoarthritis Project

9:00AM-11:00AM: Abstract Number: 2195

BMI Has Minimal Effect on Reduction of Symptoms in Patients with Osteoarthritis of the Knee Treated with Diclofenac 1% Gel

9:00AM-11:00AM: Abstract Number: 2197

Clinically Relevant Improvements in Knee Osteoarthritis Pain with Diclofenac Sodium Gel 1%

9:00AM-11:00AM: Abstract Number: 2191

Construct Validity of OMERACT Ultrasound Knee Scores with Pain, Other Symptoms, Radiographic and MRI Findings

9:00AM-11:00AM: Abstract Number: 2201

Developing a Comprehensive Patient-Specific Disease Progression Prediction Model for Knee Osteoarthritis Using Machine/Deep Learning Methods

9:00AM-11:00AM: Abstract Number: 2179

Erosive Hand Osteoarthritis, Metabolic Syndrome and Knee Osteoarthritis: A Cross-sectional Study Using Data from the PROCOAC Cohort

9:00AM-11:00AM: Abstract Number: 2180

High Molecular Weight Intraarticular Hyaluronic Acid for the Treatment of Knee Osteoarthritis: A Network Meta-Analysis

9:00AM-11:00AM: Abstract Number: 2203

Impact of Hypothetical Changes in the Use of Analgesics on the Burden of Osteoarthritis: A Population-based Microsimulation Study

9:00AM-11:00AM: Abstract Number: 2199

Is There an Association of Serum LDL, HDL and Total Cholesterol with the Development of Knee Osteoarthritis?

9:00AM-11:00AM: Abstract Number: 2196

Machine Learning Defines the Relationship Between Structural Knee Osteoarthritis and Patient-Important Outcomes: An 8-year Study of 47,858 Knee MRIs from the Osteoarthritis Initiative (OAI)

9:00AM-11:00AM: Abstract Number: 2200

Magnetic Resonance Imaging of Knee Joint Protection Following an Intra-Articular Injection of Lipid-Based Dexamethasone Sodium Phosphate Sustained Release Formulation on Subjects with Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2185

MRI-detected Abnormalities in Prediction Models of Incident Radiographic Knee Osteoarthritis over 10 Years of Follow-up

9:00AM-11:00AM: Abstract Number: 2190

Multi-vendor Multi-site T1ρ and T2 Quantification of Knee Cartilage

9:00AM-11:00AM: Abstract Number: 2181

Natural Disease Progression in Hand Osteoarthritis: Results from a Belgian Ten-years Prospective Cohort Study

9:00AM-11:00AM: Abstract Number: 2189

Reference Curves for the Knee Injury and Osteoarthritis Outcome Score in the Middle-aged Dutch Population

9:00AM-11:00AM: Abstract Number: 2183

Relation of Intra-Articular Knee Mineralization on CT to Knee Pain in People with or at Risk of Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2182

Relation of MRI-detected Structural Damage in the Knee to Anterior Knee Pain: The MOST Study

9:00AM-11:00AM: Abstract Number: 2175

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of the Anti-ADAMTS-5 Nanobody®, M6495, in Healthy Male Subjects: A Phase I, Placebo-Controlled, First-in-Human Study

9:00AM-11:00AM: Abstract Number: 2177

Sarcopenia and the Likelihood of Incident Knee Osteoarthritis and Knee Pain Among Older Adults in the Health ABC Study

9:00AM-11:00AM: Abstract Number: 2198

Severe Acute Localized Reactions Following Intra-Articular Hyaluronic Acid Injections in Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2192

Stabilization of Patellar Bone-Shape Correlates Significantly with Reduced Knee Pain Frequency After IA TPX-100 in Subjects with Bilateral Patellofemoral OA

9:00AM-11:00AM: Abstract Number: 2194

Surgical and Medical Weight Loss Threshold Dictates Decreases in Knee Osteoarthritis Pain but Not Reductions in Inflammatory Biomarkers

9:00AM-11:00AM: Abstract Number: 2174

Test-Retest Reliability and Validity of a Mobile Health Application to Automate the 30 Seconds Chair Stand Test – Preliminary Data to Create a Contemporary Instrument for Randomized Clinical Trials

9:00AM-11:00AM: Abstract Number: 2188

The Association of Plasma Fatty Acids Levels with Hand and Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2202

Trends in Prescribing of NSAIDs and Opioids Among Osteoarthritis Patients in British Columbia, Canada, 1998-2014

9:00AM-11:00AM: Abstract Number: 2186

What Is an Important Difference in Gait Speed in Adults with Knee Osteoarthritis?

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].